Image
Mini Curriculum

The Role of JAK Inhibitors in Closing Gaps in RA Management

Suggested Readings

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.

Fleischmann R, et al. Lancet. 2017;390(10093):457-468.

Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.

Strand V, et al. Arthritis Res Ther. 2015;17:362.

Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis.

Clowse MEB, et al. Drug Saf. 2016;39(8):755-762.

Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.

Pérez-Baos S, et al. Br J Pharmacol. 2017;174(18):3018-3031.

Baricitinib versus placebo or adalimumab in rheumatoid arthritis.

Taylor PC, et al. N Engl J Med. 2017;376(7):652-662.

Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease‐modifying antirheumatic drug treatment.

Fleischmann R, et al. Arthritis Rheumatol. 2017;69(3):506-517.

Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 8.4 years: an updated integrated safety analysis.

Genovese MC, et al. Ann Rheum Dis. 2020;79(suppl 10):642-643. Abstract FRI0123.

Upadacitinib monotherapy in methotrexate-naïve patients with rheumatoid arthritis: results at 72 weeks from SELECT-EARLY.

van Vollenhoven R, et al. Ann Rheum Dis. 2020;79(suppl 1):333-335. Abstract THU0217.

Long-term safety and effectiveness of upadacitinib or adalimumab in patients with rheumatoid arthritis: results at 72 weeks from the SELECT-COMPARE study.

Fleischmann R, et al. Ann Rheum Dis. 2020;79(suppl 1):323. Abstract THU0201.

Efficacy and safety of upadacitinib versus abatacept in patients with active rheumatoid arthritis and prior inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (SELECT-CHOICE): a double-blind, randomized controlled phase 3 trial.

Rubbert-Roth A, et al. Ann Rheum Dis. 2020;79(suppl 1):1015-1016. Abstract SAT0151.

Safety profile of upadacitinib up to 3 years of exposure in patients with rheumatoid arthritis.

Cohen SB, et al. Ann Rheum Dis. 2020;79(suppl 1):319-320. Abstract THU0197.

Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH 1 52-week results.

Combe B, et al. Ann Rheum Dis. 2020;79(suppl 1):320-321. Abstract THU0198.

Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis: FINCH 3 52-week results.

Westhovens R, et al. Ann Rheum Dis. 2020;79(suppl 1):1019-1020. Abstract SAT0158.

Integrated safety analysis of filgotinib treatment for rheumatoid arthritis from 7 clinical trials.

Genovese MC, et al. Ann Rheum Dis. 2020;79(suppl 1):324-325. Abstract THU0202.

Clinical efficacy of new JAK inhibitors under development. Just more of the same?

Westhovens R. Rheumatology (Oxford). 2019;58(suppl 1):i27-i33.

Efficacy and safety of switching Jakinibs in rheumatoid arthritis.

Retuerto-Guerrero M, et al. Ann Rheum Dis. 2020;79(suppl 1):648-649. Abstract FRI0132.

Thromboembolic safety reporting of tofacitinib and baricitinib: an analysis of the WHO VigiBase.

Vallejo-Yagüe E, et al. Drug Saf. 2020;43(9):881-891.

Janus Kinase Inhibitors for Rheumatoid Arthritis: Effectiveness and Value.

Institute for Clinical and Economic Review. October 11, 2019.

The Impact of Step-Therapy Policies on Patients

Snow J, et al. Xcenda AmerisourceBergen. December 4, 2019.

Treatment delays associated with prior authorization for infusible medications: a cohort study.

Wallace ZS, et al. Arthritis Care Res (Hoboken). 2019. [Epub ahead of print.]

Additional abstracts from EULAR 2020 E-Congress.

Additional abstracts from EULAR 2020 E-Congress. From June 3, 2020.

Clinician, Patient, and Caregiver Resources

Coalition of State Rheumatology Association (CSRO) Legislative Map Tool

The CSRO’s legislative map tool provides information about existing and pending step therapy, nonmedical switching, accumulator adjustment program, and uniform prior authorization laws by state and at the federal level.

American College of Rheumatology: Patient and Caregiver Resources

The ACR has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with rheumatic disease.

Arthritis Foundation

The Arthritis Foundation provides self-care tools and resources covering treatment options, pain management, diet and exercise, and common comorbidities associated with many different arthritic conditions.

European League Against Rheumatism

EULAR is an organization that represents people with arthritis/rheumatism, health professionals, and scientific societies of rheumatology of all the European nations.

NIH Health Topics: Rheumatoid Arthritis

A resource from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about rheumatoid arthritis.

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Acute Management of Migraine Attacks

Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Opioid-Induced Constipation

Proactive Diagnosis and Targeted Management

Chronic Obstructive Pulmonary Disease, Asthma, or Both

Differential Diagnosis and Comprehensive Management Strategies

Improving Outcomes in Chronic Obstructive Pulmonary Disease

Optimizing Maintenance Therapy Across Healthcare Settings

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Clinical Issues in Chronic Pain

Consensus and Controversies for Responsible Opioid Prescribing

Noninsulin Approaches to Managing Type 2 Diabetes

Best Practices in Combination Therapy

Hitting the Target in Type 2 Diabetes

Evolving Approaches to Insulin Based Therapy

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clearing the Air

Improving Outcomes for Patients with COPD

Clinical Updates in Type 2 Diabetes

New Strategies for Insulin Replacement Therapy

How Low Do You Go?

Clinical Updates in LDL-C Management

Incretin-Based Therapies For Type 2 Diabetes

Improving Comprehensive Patient Care

Improving Outcomes in Non–24-Hour Sleep-Wake Disorder

Identifying Patients and Tailoring Therapy

Comprehensive Management of Chronic Obstructive Pulmonary Disease

Collaborative Approaches to Guideline-Concordant Patient Care

Clinical Updates in the Management of Severe Asthma

New Strategies for Individualizing Long-term Care

Comprehensive Chronic Pain Management

A Focus on Patients With Opioid-Induced Constipation

Clinical Issues in Bipolar Depression

Consensus and Controversies Across the Spectrum of Patient Presentations

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Caring for Patients with Severe Asthma

Evolving Best Practices to Optimize Outcomes

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Can You Spot Axial Spondyloarthritis?

The PCP’s Role in Timely Recognition and Referral

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Advancing the Care of Severe Asthma

Differential Diagnosis, Multidisciplinary Management, and Patient Engagement

Updates in HCV Screening and Treatment

Key Issues Impacting OB/GYN Practice

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Evolving Models of HIV Care

Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Clearing the Air in Severe Asthma Management

Improving Patient Outcomes Through Shared Clinical Decision Making

GLP-1 Receptors Agonists in Type 2 Diabetes

Mechanistic Insights and Evolving Treatment Options

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

Airing It Out

A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis

COPD in Managed Care

The Clinical and Utilization Benefits of Exacerbation Prevention

Assimilating the Evidence in T2DM

Cardiovascular and Renal Outcomes With SGLT2 Inhibitors

Demystifying New Evidence for COPD Management

Best Practices for Primary Care

Finding Relief in Osteoarthritis

New Paths to Chronic Pain Management

The Changing Landscape of HIV Prevention

What the Pharmacist Needs to Know about PrEP